Accessibility Menu
MDxHealth logo

MDxHealth(NASDAQ) MDXH

Market Cap$68.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-99%
5 Year-95%
1 Year-79%
1 Month+80%
$0.73
+0.75%
+0.01Today
MDxHealth last closing stock price
MetricPriceDate
Last closeUSD 0.722026-08-28
MDxHealth stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.01%USD 0.742026-08-21
1 month+80.08%USD 0.402026-07-29
3 month-5.16%USD 0.762026-05-29
Year to date-79.81%USD 3.572025-12-31
1 year-79.17%USD 3.462025-08-28
3 year-79.41%USD 3.502023-07-14
5 year-94.78%USD 13.802021-08-20
Since inception-99.18%USD 87.502009-06-15

MDxHealth Financials at a Glance

Market Cap

$68.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$171.32M

Net Income (TTM)

-$64.22M

EPS (TTM)

-$0.73

P/E Ratio

-0.98

Dividend

$0.00

Beta (Volatility)

13420.54 (High)

Price

$0.73

Volume

182,504.084

Open

$0.71

Previous Close

$0.72

Daily Range

$0.71 - $0.73

52-Week Range

$0.40 - $5.33

Estimated Earnings Date

Aug 13, 2026

MDXH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MDxHealth

MDxHealth S.A. is a commercial-stage precision diagnostics firm specializing in urologic solutions. The company offers innovative genomic testing for prostate cancer, enabling accurate identification of clinically significant cases while reducing the need for invasive procedures.

Products and Services
  • SelectMDx: A non-invasive urine test for prostate cancer detection
  • ConfirmMDx: An epigenetic diagnostic tool for confirming prostate cancer
  • Comprehensive support services for healthcare professionals and patients
Growth Outlook
  • Revenue increased to $54.7 million in Q4 2025, showing strong market demand
  • Gross profit margin improved to 53.6% in Q4 2025, indicating operational efficiency
  • Expansion into new European markets is expected to drive future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of $146.5 million reflects a solid growth trajectory
  • Operating loss narrowed to $11.6 million in Q4 2025, showcasing improved cost management
  • Cash and cash equivalents stood at $29 million as of Q4 2025, providing liquidity for operations
MDxHealth S.A. operates in the medical diagnostics and research sector, focusing on precision medicine for prostate cancer. The company's innovative products, such as SelectMDx and ConfirmMDx, are designed to enhance patient outcomes while minimizing the risks associated with traditional diagnostic methods. With a growing international presence, particularly in the United States and Europe, MDxHealth is well-positioned to capitalize on the increasing demand for advanced diagnostic solutions. Recent financial performance indicates a positive trend, with significant revenue growth and improved gross profit margins. The company’s strategic focus on expanding its market reach and enhancing operational efficiency may attract potential investors looking for opportunities in the healthcare sector.
AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

364

CEO

Michael K. McGarrity

Website

www.mdxhealth.com

Headquarters

Herstal, WA 4040, BE

MDXH Financials

Key Financial Metrics (TTM)

Gross Margin

57.68%

Operating Margin

-16.59%

Net Income Margin

-32.17%

Return on Equity

402.97%

Return on Capital

-18.55%

Return on Assets

-17.67%

Earnings Yield

-1.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$68.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

95.42M

Volume

182.50K

Avg. Volume

5.96M

Financials (TTM)

Gross Profit

$102.02M

Operating Income

-$38.21M

EBITDA

-$21.09M

Operating Cash Flow

-$19.75M

Capital Expenditure

-$2.58M

Free Cash Flow

-$22.33M

Cash & ST Invst.

$29.03M

Total Debt

$95.11M

MDxHealth Performance Analysis

MDxHealth annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 37,054,00066.6%
20232023-12-31USD 70,193,00089.4%
20242024-12-31USD 90,049,00028.3%
20252025-12-31USD 107,875,00019.8%
MDxHealth sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-308.4%
Q42024-12-3114.4%
Q22025-06-30-44.6%
Q42025-12-31105.5%
MDxHealth annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.7816.7%
20232023-12-31USD -1.66-40.1%
20242024-12-31USD -1.16-30.4%
20252025-12-31USD -0.67-42.1%
MDxHealth sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-303.9%
Q42024-12-3147.9%
Q22025-06-3021.1%
Q42025-12-31-23.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$54.67M

+41.1%

Gross Profit

$29.31M

+16.2%

Gross Margin

53.61%

N/A

Market Cap

$68.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$188.92K

N/A

Employees

364

N/A

Net Income

-$18.78M

+9.6%

EBITDA

-$6.74M

+60.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$29.03M

+29.7%

Total Debt

$95.11M

+130.5%

Accounts Receivable

$14.68M

+30.2%

Inventory

$6.74M

+142.6%

Long Term Debt

$93.22M

+138.1%

Short Term Debt

$1.90M

-10.6%

Return on Assets

-17.67%

N/A

Return on Invested Capital

-13.70%

N/A

Free Cash Flow

$324.00K

+102.4%

Operating Cash Flow

$378.00K

+103.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNWVSANUWAVE Health Inc.
$4.71+0.75%
QTRXQuanterix Corporation
$2.62-0.95%
XGNExagen Inc.
$7.36-0.47%
IMRXImmuneering Corporation
$4.93-1.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.54-0.18%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.88+0.10%
NUNu Holdings
$14.48+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.66+0.02%

Questions About MDXH

What is the current price of MDxHealth?

MDxHealth is trading at $0.73 per share.

What is the 52-week range for MDxHealth?

Over the past 52 weeks, MDxHealth has traded between $0.40 and $5.33.

How much debt does MDxHealth have?

As of the most recent reporting period, MDxHealth reported total debt of $105.85M.

How much cash does MDxHealth have on hand?

MDxHealth reported $19.21M in cash and cash equivalents in its most recent financial results.

What is MDxHealth’s dividend yield?

MDxHealth does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services